Welcome to Chengdu
for the symposium
Chengdu is the capital of Sichuan province, which is one of the most famous historical and cultural cities in China, Chengdu is famous for the lovely pandas and spicy hot pots, and has been dubbed as The City of Gastronomy by the United Nations Educational, Scientific and Cultural Organization.
As for the economy, Chengdu has been the top of the new first-tier cities of China ever since 2016, and keeps attracting more and more investments and worldwide companies to settle here.
Chengdu Municipal Talents Work Leading Group Office
Fiscal & Financial Bureau of Chengdu Hi-tech Zone
Association of Chengdu Talent Development and Promotion
Chengdu Institute for Food and Drug Control
Association of Chengdu High-Tech Zone Bio-Pharmaceutical Industry
Shanghai Truesaw Healthcare Consulting Co., Ltd.
Chengdu Institute of Migrant Talent Management
Seminar of Investment and Financing in Biopharmaceutical Industry of Chengdu Institute of Migrant Talent Management
Agenda
- 08:00 - 16:00 Registration
- Grand Ballroom
-
09:00 - 09:40
Opening Ceremony
Host: Jin Li(Chairman & CEO, HitGen Inc.)
09:00 - 09:15 Opening Remarks
Xianping Lu, Chairman & CEO of Chipscreen Biosciences Co., Ltd.
09:15 - 09:25 Government Officials
Government Officials of Sichuan Province and Chengdu
09:25 - 09:40 Introduction of Chengdu Tianfu International Bio-Town
-
09:40 - 12:25
Speech 1：Analysis of Global Industrial Trends and Policies, Frontiers in Innovative Drug R&D
Host: Jin Li(Chairman & CEO, HitGen Inc.)
09:40 - 10:10 Synthetic Biology and R&D of Natural Medicines
Guoping Zhao, Academician of Chinese Academy of Sciences
10:10 - 10:40 Perspectives on Dual Filing of INDs with NMPA and US FDA
Chunlin Chen, CEO of Shanghai Medicilon Inc.
10:40 - 10:55 Tea Break
10:55 - 11:25 Scientific and Regulatory Considerations in Characterizing the Translational Safety, Pharmacology, and Toxicity of Biopharmaceutical Medicines
Rakesh Dixit, President& CEO of Bionavigen Consulting and Drug Development
11:25 - 11:55 Accelerating Innovation Worldwide
Dan Wang, Head of Johnson & Johnson Innovation Asia Pacific
11:55 - 12:25 Discovery & Development of Novel Narcotic Drugs Involve Medical Doctors from the Very Beginning with Full Participation
Jin Liu, Director of Anesthesia Operation Center of Huaxi Hospital, The First Chairman of Chinese Association of Anesthesiologists
- 12:25 - 13:30 Lunch Break
-
13:30 - 17:45
Speech 2：Innovative Drug R&D Case Studies
Host: Mingde Xia (Senior Director, Johnson & Johnson Innovation Asia-Pacific)
13:30 - 14:00 The Discovery of MK-8719, a Potent O-Glcnacase Inhibitor as a Potential Treatment for Tauopathies
Joseph Duffy Executive Director and Head of Externd Discovery Chemistry of Merck Research Laboratories
14:00 - 14:30 GFH018, a Clinical Stage Selective TGF-β1 Inhibitor Targeting Tumor Associated Microenvironment
Qiang Lv, Founder & Chairman of GenFleet Therapeutics Inc.
14:30 - 15:00 Utility of DNA-Encoded Libraries in Drug Discovery: LG Chem Perspectives
Hee Dong Park, Research Fellow/Team Leader, Drug Discovery Center, Life Sciences R&D of LG Chem
15:00 - 15:30 A Tale of Two Best-in-Class Therapies: BTK Inhibitor Zanubrutinib and PD1 Antibody Tislelizumab
Mike Liu, Vice President of Biology of BeiGene (Beijing) Co., Ltd.
15:30 - 15:45 Tea Break
15:45 - 16:15 Unmet Needs in Clinical Therapy of Diabetes and Relevant R&D Activities in Chipscreen
Desi Pan, Head of the Center of Early Research and Development of Shenzhen Chipscreen Biosciences Co., Ltd.
16:15 - 16:45 Developing First-in-Class LAT1 Transporter Targeted Therapy for Brain Tumors
Frank Yan, General Manager of N.B. Quadriga Medical Technology Co. Ltd.
16:45 - 17:15 Discovery of a DPP-4 Inhibitor
Qiang Yv, CEO of CGeneTech (Suzhou, China) Co., Ltd.
17:15 - 17:45 Structural Basis of Molecular Modulation of Human Cannabinoid Receptors
Zhijie Liu, ShanghaiTech University iHuman Institute of ShanghaiTech University iHuman Institute
- Junior Ballroom
-
13:30 - 14:10
Keynote Speech
Crisis and Reconstruction：The Development of the Pharmaceutical Industry Under the New Medical Insurance and New Drug Supervision
Peng Zou, Executive Ditector of Research Department of China International - 14:10 - 17:45 Roadshows
-
09:00 - 11:20
Speech 3：Application of Frontier Technologies in Innovative Drug R&D
Host: Xiang Gao (Chairman, GemPharmatech Co., Ltd.)
09:00 - 09:30 Application of Animal Models in Preclinical Study
Xiang Gao, Chairman of GemPharmatech Co., Ltd.
09:30 – 10:00 Tea Target Protein Degradation in Drug Discovery
Han Dai, Discovery Biology Executive Director of BeiGene (Beijing) Co., Ltd.
10:00 – 10:30 Mimic Human Cancers in vitro/in vivo by Building the Largest Matched Patient-derived Disease Library for Translational Oncology Research
Henry Li, Chief Scientific Officer of Crown Bioscience Inc.
10:30 - 10:45 Tea Break
10:45 - 11:20 Panel Discussion Application of Frontier Technology in innovative Drug R&D
Xiang Gao, Chairman of GemPharmatech Co., Ltd. (Moderator)
Yuanwei Chen, Founder & CEO of Hinova Pharmaceuticals Inc.
SiXiang Zhou, Senior Director, Business Development, APAC Head of Harbour BidMed Co., Ltd.
Henry Li, Chief Scientific Officer of Crown Bioscience Inc.
-
11：20-12：30
Speech 4：The Current State of Innovative Drug Investment and Exit
11：20-11：55 Panel Discussion Innovative Drug Projects: the View of VC, Starup and Big Pharm
Yuanwei Chen, Founder & CEO of Hinova Pharmaceuticals Inc. (Moderator)
Karen Liu, Partner of 3E BioVentures
Chunlin Zhao, Founder & Managing Partner of Anlong Fund
Gerald Shipps，Senior Director & Emerging Science Lead of Pfizer Worldwide Research, Development and Medical
Bin Shi, Chief Strategic Officer of Deuracor Therapeutics Inc.
11：55-12：30 Panel Discussion Innovative Drug Projects: The Latest Trend of Investment and Exit
Tao Han, Vice President of CICC Capital (Moderator)
Li Zhang, Partner of CDH Investments
Haigang Chen, Managing Partner of Apricot Capital
Teresa Zhou, Partner of YUNION Health Venture
Michael Xue, Managing Director of Morningside Venture Capital - 12:30 - 13:30 Lunch Break
-
13:30 - 17:15
Speech 5：Clinical Study and Translational Medicine
Host: Feng Bian (Senior Director and Asia Emerging Science Lead, Pfizer Asia Discovery Labs (ADL)
Host: Min Wu (Executive Director, Asia Pacific Innovation Hub, BD&L, MSD R&D (China) Co., Ltd.
13:30 - 14:00 Future Opportunities and Challenges of Nucleotide-based Experimental and Diagnostic Techniques
Jun Yv, Co-founder of Beijing Institute of Genomics, Chinese Academy of Sciences
14:00 - 14:30 The JAK-STAT Pathway to Th-GM and Clinical Applications
Xinyuan Fu, Senior Chair Professor of West China Hospital
14:30 - 15:00 Pharmacogenomics Guides Individualized Drug Therapy
Songnian Hu, Researcher, Institute of Microbiology, Chinese Academy of Sciences
15:00 - 15:30 Biomarker-Driven Clinical Development in China - a Case Study of Savolitinib
Ye Hua, Chairman & CEO of BioNova Pharmaceuticals Ltd.
15:30 - 15:45 Tea Break
15:45 - 16:15 A New Approach for Oncology Translation Medicine
Bin Peng, Chief Medical Officer of EpimAb Biotherapeutics Inc.
16:15 - 16:45 Dose Regimen Optimization: Value Driven and Risk Control
Jin Yang, Professor of China Pharmaceutical University Center for Drug Evaluation
-
17:15 - 17:30
Closing Remarks
Jin Li, Chairman & CEO of HitGen Inc. - Junior Ballroom
-
09:00 - 09:40
Keynote Speech
The IB and PE Combined to Evolute the New Ecology of Pharmaceutical Investment
Tao Han, Vice President of CICC Capital
- 09:40 - 12:00 Roadshows
-
13:30 - 14:10
Keynote Speech
New Opportunities for IPO, Interpretation of Pharmaceutical and Medical Companies STAR Market and HKEx Listing
Weixian Zhang, Executive Director of Investment Banking Department of China International Capital Co., Ltd.
- 14:10 - 16:40 Roadshows
- 17:30 Registration
- 18:00 Welcome Dinner
Speaker More >>
Dr. Guoping Zhao
Confirmed
Dr. Chunlin Chen
Confirmed
Dr. Rakesh Dixit
Confirmed
Dr. Dan Wang
Confirmed
Dr. Jin Liu
Confirmed
Dr. Joseph Duffy
Confirmed
Dr. Qiang Lv
Confirmed
Dr. Mike Liu
Confirmed
Dr. Desi Pan
Confirmed
Dr. Songnian Hu
Confirmed
Dr. Zhijie Liu
Confirmed
Dr. Ye Hua
Confirmed
Dr. Bin Peng
Confirmed
Dr. Han Dai
Confirmed
Ms. Li Zhang
Confirmed
Dr. Chunlin Zhao
Confirmed
Dr. Bin Shi
Confirmed
Mr. Michael Xue
Confirmed
Dr. Karen Liu
Confirmed
Ms. Teresa Zhou
Confirmed
Dr. Xinyuan Fu
Confirmed
Dr. Jun Yv
Confirmed
Dr. Xiang Gao
Confirmed
Dr. Qiang Yv
Confirmed
Dr. Frank Yan
Confirmed
Committee
Dr. Jin Li
Dr. Feng Bian
Dr. Xiang Gao
Dr.Xianping Lu
Dr.Min Wu
Dr. Mingde Xia
Dr. Matthew Tremblay
Dr. Bo Chen
Sponsor & Exhibit
Sponsors can enjoy the rights including co-promotion and more involvement in the symposium. Sponsors will have many privileges such as exclusive 1-on-1 partnering room, exhibition booth and the priority to apply for a keynote speech, roadshow or poster presentation.
2018 Symposium, 1400+ worldwide participants, 680+ pharma, biotech, CRO, research institutes, and government organizations, 70+ KOL speakers, and 20+ sponsors including Shanghai Medicilon, GenScript Biotech, Sundia Meditech, Thermofisher Scientific, SHIMADZU etc. participated.
Ruyi Yan ry.yan@hitgen.com +86 28 85197385-8807
Roadshow
Free roadshow opportunities are open to worldwide drug discovery R&D projects. Many industrial KOLs and investors will help you success and your project could be the hottest one. Please fill out the information, we will contact you after review.
Poster Presentation
Free poster presentation opportunities are open to worldwide drug discovery R&D projects. The poster should be designed according to requirements below. Please send the poster to conference@hitgen.com , we will contact you after review.
Travel & Hotel
Marriott Hotel Financial Centre, No. 999 Tianfu Avenue North, High-Tech Zone, Chengdu, Sichuan, China
Distance
Shuangliu Airport 20 km
East train station 12 km
Surrounding Hotels
228 fucheng avenue east section, gaoxin district, wuhou district, chengdu
300 m away from the venue
228 fucheng avenue east section, gaoxin district, wuhou district, chengdu
300 m away from the venue
About
The International Symposium on the Frontiers and Practice of Innovative Drug R&D has been held in Chengdu, the international gateway hub in western China, ever since 2016. The goal of symposium is to build an international bio-pharmaceutical ecosystem and an information sharing platform for cutting-edge technology of innovative drug R&D, and to connect worldwide innovations as well as promote cross-border cooperation.
History
The first symposium was initiated and organized by HitGen Inc., with its leading technology in the DNA encoded chemical libraries (DELs) area, and successfully held in November 2016 with Pfizer Asia Discovery Labs.
The second symposium was organized by HitGen Inc. and other domestic leading pharmaceutical companies including Chipscreen Biosciences Inc. and ConMed Biosciences Inc..
In 2018, more than 1400 worldwide participants came to the third symposium, among those there were nearly 200 overseas attendees, more than 70 KOL speakers and 680 pharma, biotech, CRO, research institutes, and government organizations. Meanwhile, the 8th International Symposium on DNA-Encoded Chemical Libraries was held in Chengdu, China for the first time and cooperated with the International Symposium on the Frontiers and Practice of Innovative Drug R&D, now it will be held in Boston, Zurich and Chengdu alternatively.
